Vendor Intelligence Report: Biolabshop Limited

Executive summary

Across 6 Finnrick lab tests, Biolabshop Limited records 1 pass / 5 fail — an overall pass rate of 17%. The product signal is uneven but not encouraging: BPC-157 and Ipamorelin have no passing Finnrick samples, while PT-141 is the least-bad tested peptide at one pass and one fail. Ratings also contract under stricter grading, so the caution is not a quirk of one methodology view.

The corporate record is more complex than the brand name suggests. UK filings identify the namesake company and a second UK company under the same recorded controller; storefront terms and archived captures then add Spanish, Polish, German, and UAE nodes. Current regional terms place the reviewed storefronts under a UAE seller-of-record, creating a practical accountability gap when payment, returns, customs, or product disputes arise.

Public reputation signals split sharply by domain. A claimed UK Trustpilot profile looks materially better than the EU profile, despite contact-overlap signals; recent complaints also point to card-payment disruption, alleged card compromise, and a shift toward wire transfers. The report separates these consumer allegations from proven breach findings, but treats the payment-redress pattern as buyer-relevant.

For peptide selection, this is not a broad green light. Biolabshop looks least defensible for BPC-157 and Ipamorelin on the current Finnrick record; PT-141 is only directionally less weak and still below a repeated-passing profile. The dossier also maps biolabshopuk.co.uk and biolabshopofficial.co.uk as unresolved lookalike paths, plus the U.S. tirzepatide import case where a terminated investigation still leaves a General Exclusion Order as the buyer-relevant risk.

Inside the full report:

• Appendix A per-product Finnrick laboratory data and methodology-divergence charts for all 3 tested products
• UK Companies House exhibits for Biolabshop Limited, TDJKZ Limited, and recorded director/PSC control
• Cross-border operator-chain analysis covering UAE, Spanish, Polish, German, and UK entities
• Storefront and redirect map distinguishing regional Biolabshop domains from lookalike sites
• Trustpilot and payment-redress analysis, including split profiles, wire-transfer claims, and card-fraud allegations
• USITC 337-TA-1377 tirzepatide timeline and General Exclusion Order implications

Risk assessment

• Tested-product quality risk — high: Finnrick’s Biolabshop record is 6 tests (1 pass / 5 fail); BPC-157 at 44.56% and Ipamorelin at 61.85% have zero passing tests, while PT-141 is 59.41% with 1 pass / 1 fail.
• Payment and buyer-redress risk — high: A 22 June 2026 Trustpilot review says card payments were removed in favor of wire transfers, and earlier reviews allege card compromise and funds captured despite payment-failed messages.
• Copycat and brand-confusion risk — high: Impersonation/lookalike sites biolabshopuk.co.uk and biolabshopofficial.co.uk were observed, while no authoritative official-channel list, authorized-reseller list, or anti-counterfeit verification route surfaced.
• Cross-border operator opacity risk — high: Current regional terms list UAE-based VisionaryEdge while UK, Spanish, Polish and German entities remain in the operating history, complicating accountability, returns and dispute resolution.
• Reputation-management risk — medium: Trustpilot profiles with identical contact details diverge sharply: biolabshop.eu 2.2/5 across 36 reviews versus claimed biolabshop.co.uk 4.0/5 across 450 reviews.
• Tirzepatide import-exclusion risk — medium: USITC Investigation 337-TA-1377 is terminated, but a General Exclusion Order remains in effect for covered tirzepatide products shipped to the United States.